Skip to main content
. 2023 Feb 11;11(2):528. doi: 10.3390/biomedicines11020528

Figure 2.

Figure 2

CNP (carboplatin and nab-paclitaxel), BEVCP (bevacizumab, carboplatin, and paclitaxel), and DOC (docetaxel). Forest plot of the adjusted association between antibiotic use and prognosis by study arm in the cohort randomised therapies without atezolizumab. Median time to progression-free survival (PFS) and overall survival (OS) are unadjusted. (A) Forest plot of association of antibiotics with PFS. (B) Forest plot of association of antibiotics with OS. (C) Forest plot of association of antibiotics with objective response rate (ORR).